Third Rock biotech startups find work-share partner in Cytokinetics

Cytokinetics' Robert Blum.

There's a line of thought in the cash-sucking biotech world that once a small company gets a drug into the clinic -- especially if investors want to accelerate their return -- that it winds down research operations. Robert Blum doesn't buy it. Instead, the president and CEO ofCytokinetics Inc. (NASDAQ: CYTK) has discovered a way to help pay for his research staff while awaiting the results of a handful of clinical trials: Rent out their expertise.